CHRS: Gunggung dhuwit awis saben saham coherus.com

The oncology drug market is currently expanding rapidly, allowing Coherus Biosciences (CHRS) to grow its customer base through new immunotherapies. This enables the company to pivot from biosimilars toward its own proprietary antibodies to combat pricing pressure. Marketing and production efficiency is maintained by leveraging external logistics partners. Cash per share trends visualize liquidity, where the value of 0.55 captures the metric level.
Rincian analitis perusahaan Coherus Biosciences

Coherus Biosciences (CHRS) is currently undergoing a rigorous transformation, shifting its focus from biosimilars to the development of its own immuno-oncology platform to return to profitability. This metric measures the volume of liquid assets per share, allowing the cash per share data on GURU.Markets to determine whether the decline in share price is outpacing the actual reduction of capital during this period of business restructuring.